Prokidney (PROK) Non-Current Deffered Revenue (2021 - 2022)
Prokidney's (PROK) quarterly Non-Current Deffered Revenue came in at $7.7 million in Q2 2022, little changed on a QoQ basis from $7.7 million in Q1 2022.
Prokidney (PROK) Non-Current Deffered Revenue (2021 - 2022) Analysis & Trends
Prokidney (PROK) has 2 years of Non-Current Deffered Revenue data on file, last reported at $7.7 million in Q2 2022.
- On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $7.7 million in Q2 2022; TTM through Jun 2022 was $7.7 million, a N/A change from a year earlier, with the FY2021 full-year figure at $7.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q2 2022 stood at $7.7 million, roughly flat from $7.7 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for PROK reached as high as $7.7 million in Q3 2021 and fell as low as $7.7 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Prokidney | 96.00 Mn | 96.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 7.70 Mn |
| Mar 31, 2022 | 7.70 Mn |
| Dec 31, 2021 | 7.70 Mn |
| Sep 30, 2021 | 7.70 Mn |